CHI3L1 and rheumatoid arthritis: Anti-TNF-α treatment suppresses the CHI3L1 gene expression in the cells obtained from RA patients, and significantly reduces YKL-40 concentrations in serum of PsA patients, thus providing a potential tool for monitoring the effectiveness of the anti-TNF-α molecules (80, 81).